Literature DB >> 33777174

Cancer of the anal canal, a reality in the Colombian coffee region. Clinical-epidemiological review 2000-2019.

Carlos Raúl Villegas Mejía1,2, Manuel Villegas Jaramillo3,4, Pedro Villegas Jaramillo3,5.   

Abstract

INTRODUCTION: Anal cancer is a rare pathology which has increased over the last few decades, and, therefore, gained importance for the quality of life of affected individuals. Thus, a review has been conducted in the Colombian coffee region (Departments of Caldas, Quindío y Risaralda) describing its behaviour and clinical-epidemiological profile.
MATERIALS AND METHODS: Descriptive review of 437 patients of Western SAS Oncologists between January 2000 and December 2019 with a diagnosis of anal cancer.
RESULTS: 62% of cases presented in women with a median age of 62 years, 30% in the sixth decade; centred at 65% in three main cities designated as capitals (Manizales, Pereira and Armenia); 62% as localised disease, with 40% stage II-A and 6% as initial metastasis; 29% presented positive ganglia, particularly N1a; squamous cell or epidermoid histology in 90%; 16% poorly differentiated; 5% related to Human Immunodeficiency Virus infection; localisation in the medial area of the anal canal in 63% of cases; 83% completed treatment, and 92% of them received chemotherapy/radiation therapy with 87% based on the Nigro protocol; finally, 11% presented with relapse in the liver in 10% of cases and 55% local.
CONCLUSION: Four hundred and thirty-seven patients evaluated over 20 years with follow up at median 34.13 months (standard deviation 41.75) with median survival at later ages decreasing to 62% in patients older than 80 years, and differences in survival in localised disease at 78% in comparison to 46% in advanced metastasis. Finally, the overall 5-year survival rate is 69% with a median survival of 191 months in the study. © the authors; licensee ecancermedicalscience.

Entities:  

Keywords:  anal canal; anal cancer; epidemiology; profile; review

Year:  2021        PMID: 33777174      PMCID: PMC7987495          DOI: 10.3332/ecancer.2021.1181

Source DB:  PubMed          Journal:  Ecancermedicalscience        ISSN: 1754-6605


  33 in total

Review 1.  Adenocarcinoma of the anal canal - a systematic review.

Authors:  S Anwar; H Welbourn; J Hill; D Sebag-Montefiore
Journal:  Colorectal Dis       Date:  2013-12       Impact factor: 3.788

2.  Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; P J Nilsson; C Aschele; V Goh; D Peiffert; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2014-07-06       Impact factor: 32.976

3.  Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.

Authors:  Anne Gry Bentzen; Marianne G Guren; Eva H Wanderås; Gunilla Frykholm; Kjell M Tveit; Tom Wilsgaard; Olav Dahl; Lise Balteskard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-19       Impact factor: 7.038

4.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.

Authors:  Mahul B Amin; Frederick L Greene; Stephen B Edge; Carolyn C Compton; Jeffrey E Gershenwald; Robert K Brookland; Laura Meyer; Donna M Gress; David R Byrd; David P Winchester
Journal:  CA Cancer J Clin       Date:  2017-01-17       Impact factor: 508.702

5.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

Authors:  H Bartelink; F Roelofsen; F Eschwege; P Rougier; J F Bosset; D G Gonzalez; D Peiffert; M van Glabbeke; M Pierart
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

6.  Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Authors:  Edgar Ben-Josef; Jennifer Moughan; Jaffer A Ajani; Marshall Flam; Leonard Gunderson; JonDavid Pollock; Robert Myerson; Rani Anne; Seth A Rosenthal; Christopher Willett
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

7.  A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer.

Authors:  Renata D'Alpino Peixoto; Dante D Wan; Devin Schellenberg; Howard J Lim
Journal:  J Gastrointest Oncol       Date:  2016-08

8.  Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.

Authors:  Leonard L Gunderson; Jennifer Moughan; Jaffer A Ajani; John E Pedersen; Kathryn A Winter; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-10       Impact factor: 7.038

9.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

10.  Oncologic outcomes of salvage surgery for epidermoid carcinoma of the anus initially managed with combined modality therapy.

Authors:  Robert P Akbari; Philip B Paty; Jose G Guillem; Martin R Weiser; Larissa K Temple; Bruce D Minsky; Leonard Saltz; W Douglas Wong
Journal:  Dis Colon Rectum       Date:  2004-05-28       Impact factor: 4.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.